Utility of natriuretic peptides for detecting left ventricular hypertrophy and dysfunction: the framingham study

Ramachandran S. Vasan; Martin G. Larson; Eric Leip; Emelia Benjamin; Thomas J. Wang; Patrice Sutherland; Peter W.F. Wilson; Daniel Levy

doi:10.1016/s0735-1097(02)80890-7

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2002

Plasma Natriuretic Peptides for Community Screening for Left Ventricular Hypertrophy and Systolic Dysfunction

Ramachandran S. Vasan, Emelia Benjamin, Martin G. Larson, Eric Leip, Thomas J. Wang, Peter W.F. Wilson, Daniel Levy

Article2017

Epidemiology of Left Ventricular Systolic Dysfunction and Heart Failure in the Framingham Study

Ramachandran S. Vasan, Vanessa Xanthakis, Asya Lyass, Charlotte Andersson, Connie W. Tsao, Susan Cheng, Jayashri Aragam, Emelia Benjamin, Martin G. Larson

Article2013

Association of Novel Biomarkers of Cardiovascular Stress With Left Ventricular Hypertrophy and Dysfunction: Implications for Screening

Vanessa Xanthakis, Martin G. Larson, Kai C. Wollert, Jayashri Aragam, Susan Cheng, Jennifer E. Ho, Erin Coglianese, Daniel Levy, Wilson S. Colucci, G. Michael Felker, Emelia Benjamin, James L. Januzzi, Thomas J. Wang, Ramachandran S. Vasan

Article2000

Comparison of electrocardiographic criteria for diagnosis of left ventricular hypertrophy in hypertension: the MAVI study.

Paolo Verdecchia, Emilio Vincenzo Dovellini, M Gorini, G Gozzelino, Donata Lucci, A Milletich, Aldo Maggioni

Article2005

Different Normalizations for Body Size and Population Attributable Risk of Left Ventricular Hypertrophy: The MAVI Study

Giovanni de Simone, R Devereux, Aldo Maggioni, Marco Gorini, O Dedivitiis, Paolo Verdecchia